Biotech Stock Shifts
Institutional Investors Adjust Holdings in Biotech: Voss Capital Trims Kura, Others Increase Stakes
Anonymous
Key Points
1
In addition to Voss Capital’s 90.3% reduction in Kura Oncology, several other institutions increased exposure—e.g., Jacobs Levy Equity Management boosted its stake by 101.6% to 2,224,590 shares (valued at $19,688,000), and Renaissance Technologies increased by 111.6% to 1,830,566 shares (valued at $19,020,000).
2
For Krystal Biotech, the SEC-disclosure coverage also noted a company-insider sale: EVP John Charles Thomas sold 642 shares at an average price of $302.03, for total proceeds of $193,903.26 (reported in a filing on May 26).
3
Other Krystal Biotech buying activity besides Rhenman was also detailed, including Castleark Management LLC buying a new stake valued at $7,214,000 and State Board of Administration of Florida Retirement System increasing its position by 172.4% to 15,756 shares (valued at $3,884,000).
4
On Janux Therapeutics, the filings coverage quantified broader institutional ownership and additional movers: hedge funds and other institutional investors owned 75.39% of JANX, and California State Teachers Retirement System increased its stake by 1.1% to 37,139 shares (valued at $858,000).
5
For Kura Oncology’s analyst sentiment shift, Zacks Research specifically raised the stock from “strong sell” to “hold” in a research note dated February 26, and Wells Fargo set a $24.00 price target (as cited in the coverage of the rating change).
Voss Capital LP slashed its Kura Oncology stake by 90.3% in the fourth quarter, cutting its position to just 29,737 shares worth roughly $309,000, according to MarketBeat. The near-total exit stands in sharp contrast to moves by other big investors, who were buying the same stock at the same time.
The diverging bets reveal a split on Wall Street over which biotech names are worth holding — and which have peaked. While Voss was selling Kura, firms like Rhenman & Partners Asset Management AB were doubling and tripling down on other NASDAQ-listed biotechs, per recent SEC disclosures reviewed by WhaleWisdom.
Voss Capital Exits Kura While Others Double Down
Voss Capital's retreat left it with a token $309,000 position in Kura Oncology (KURA). Yet two other large funds moved the opposite way. Jacobs Levy Equity Management boosted its Kura stake by 101.6%, reaching 2,224,590 shares valued at $19.7 million. Renaissance Technologies raised its position by 111.6% to 1,830,566 shares worth $19 million, per MarketBeat.
The split reflects competing views on Kura's pipeline drug ziftomenib. The FDA accepted a New Drug Application for the drug — used in a rare blood cancer called AML — with a review deadline of November 30, 2025, according to GlobeNewswire. Voss Capital appears to have adopted a "sell the news" strategy, reducing risk before the commercial launch hurdles ahead. Kura's stock has lost 8.5% year-to-date in early 2026 and still posts quarterly losses of $0.83 per share, per Zacks Investment Research.
Zacks Upgrades Kura From 'Strong Sell' to 'Hold'
On February 26, Zacks Research raised its Kura Oncology rating from "strong sell" to "hold," according to MarketBeat. The move signals a stabilization in analyst sentiment rather than outright enthusiasm. Wells Fargo set a $24.00 price target on the stock. Still, the "hold" label suggests analysts are watching — not buying — for now.
Kura CEO Troy Wilson said the company is "well-positioned to deliver meaningful benefit to patients" after the FDA acceptance. Revenue for Q1 2026 came in at $18.27 million, beating estimates by 21.3%, per Zacks Investment Research. That beat may explain why some institutions held their nerve while Voss walked away.
Rhenman Pours Money Into Krystal Biotech and Janux
Rhenman & Partners Asset Management AB made aggressive moves across multiple biotech names in Q4. The Swedish healthcare-focused fund raised its Krystal Biotech (KRYS) stake by 112.8%, adding 13,250 shares to reach roughly 25,000 shares worth $6.16 million, per watchlistnews.com. Castleark Management LLC also bought a brand-new Krystal position worth $7.2 million. Florida's State Board of Administration raised its holding by 172.4% to 15,756 shares worth $3.88 million, per MarketBeat.
On Janux Therapeutics (JANX), Rhenman boosted its stake by 125.1% to 225,377 shares valued at $3.11 million, according to tickerreport.com. Hedge funds and institutional investors now own 75.39% of Janux's float — meaning big-money players, not retail traders, will drive price swings. Rhenman's Hugo Schmidt called recent weakness a "dip" and said the firm views Janux as undervalued despite cautious readings of early clinical data.
Krystal Biotech Insider Sells All Direct Shares at $302
On May 26, Krystal Biotech EVP and General Counsel John Charles Thomas sold 642 shares at an average price of $302.03, collecting $193,903.26 in total proceeds, per an SEC Form 4 filing cited by Investing.com. The sale cleared out his entire directly held common stock position. The filing was formally disclosed on May 27.
Analysts at Investing.com called the sale "routine" because Thomas had set up a Rule 10b5-1 trading plan back on February 23 — a pre-scheduled arrangement that removes the appearance of insider timing. Even so, some traders flagged it as a cautionary signal. Krystal stock was trading near its 52-week high of $319.48 at the time, and the company had just reported Q1 2026 net income of $55.9 million on the back of a 32% jump in VYJUVEK gene-therapy revenue to $116.4 million, per GuruFocus.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
17
Reach
33
A
AnonymousAuthor
